Because ABL allosteric inhibitors are currently in clinical trials for the treatment of therapy-resistant leukemia patients [48], these inhibitors could be employed to impair MMP9 secretion and function in metastatic lung adenocarcinoma cells primed by MSCs. The gene discussed is MMP9; the disease is leukemia.